NEW YORK (GenomeWeb News) – BioFocus DPI said this week that it has extended a drug screening pact with drug giant Eli Lilly until the end of 2009.

Under terms of the deal, BioFocus, which is the service division of Galapagos, will identify active compounds by screening Lilly's library of drug candidates. BioFocus has been conducting research work on compounds that target specific cellular signal transduction pathways for Lilly since March 2005.

Financial and other terms of the collaboration were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Sponsored by

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Sponsored by

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.